Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.44
CERC's Cash-to-Debt is ranked lower than
96% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CERC: 0.44 )
Ranked among companies with meaningful Cash-to-Debt only.
CERC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 2.18 Max: No Debt
Current: 0.44
0.14
No Debt
Equity-to-Asset 0.29
CERC's Equity-to-Asset is ranked lower than
84% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CERC: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
CERC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.12  Med: 0.34 Max: 0.78
Current: 0.29
-0.12
0.78
Debt-to-Equity 0.79
CERC's Debt-to-Equity is ranked lower than
79% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. CERC: 0.79 )
Ranked among companies with meaningful Debt-to-Equity only.
CERC' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.5  Med: 0.48 Max: 11.37
Current: 0.79
-3.5
11.37
Debt-to-EBITDA -0.48
CERC's Debt-to-EBITDA is ranked higher than
61% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. CERC: -0.48 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CERC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.51  Med: -0.42 Max: -0.15
Current: -0.48
-0.51
-0.15
Piotroski F-Score: 1
Altman Z-Score: -1.98
Beneish M-Score: 124.68
WACC vs ROIC
10.99%
-143.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -230.83
CERC's Operating Margin % is ranked higher than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CERC: -230.83 )
Ranked among companies with meaningful Operating Margin % only.
CERC' s Operating Margin % Range Over the Past 10 Years
Min: -1394.62  Med: -672.34 Max: 49.94
Current: -230.83
-1394.62
49.94
Net Margin % -241.29
CERC's Net Margin % is ranked higher than
86% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CERC: -241.29 )
Ranked among companies with meaningful Net Margin % only.
CERC' s Net Margin % Range Over the Past 10 Years
Min: -1428.62  Med: -692.97 Max: 42.68
Current: -241.29
-1428.62
42.68
ROE % -183.97
CERC's ROE % is ranked higher than
85% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CERC: -183.97 )
Ranked among companies with meaningful ROE % only.
CERC' s ROE % Range Over the Past 10 Years
Min: -247.87  Med: -96.25 Max: 55.38
Current: -183.97
-247.87
55.38
ROA % -70.53
CERC's ROA % is ranked higher than
94% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CERC: -70.53 )
Ranked among companies with meaningful ROA % only.
CERC' s ROA % Range Over the Past 10 Years
Min: -256.99  Med: -120.12 Max: 48.56
Current: -70.53
-256.99
48.56
ROC (Joel Greenblatt) % -62641.11
CERC's ROC (Joel Greenblatt) % is ranked higher than
100% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CERC: -62641.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CERC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -62641.11  Med: -29756.76 Max: 31568.18
Current: -62641.11
-62641.11
31568.18
GuruFocus has detected 4 Warning Signs with Cerecor Inc CERC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CERC's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CERC Guru Trades in

CERC Guru Trades in

Q2 2018

CERC Guru Trades in Q2 2018

Chuck Royce 1,414 sh (New)
» More
Q3 2018

CERC Guru Trades in Q3 2018

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CERC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BLPH, NAS:SRRA, XTAE:RDHL, NAS:INFI, LSE:MTFB, ROCO:4130, NAS:KMPH, LSE:ERGO, NAS:CRIS, OTCPK:DGJI, XTAE:CBI, TPE:4737, WAR:BIO, XPAR:ADOC, ROCO:6589, NAS:ALPN, NAS:AVXL, XSWX:SANN, NAS:OMED, TSE:2191 » details
Traded in other countries:C6K.Germany,
Headquarter Location:USA
Cerecor Inc is a clinical?stage biopharmaceutical company which is engaged in developing drug candidates for patients with neurological and psychiatric disorders.

Cerecor Inc is a clinical?stage biopharmaceutical company operating in the US. It is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The company holds a portfolio of novel clinical and preclinical compounds that we are developing for a variety of indications including CERC-301 which is an oral, adjunctive treatment of patients with major depressive disorder (MDD); CERC-501 which is for substance use disorders and adjunctive treatment of MDD and CERC-406 which is preclinical candidate of compounds that inhibit catechol?O?methyltransferase (COMT) within the brain. The company owns a right to COMTi platform is an enzyme that is critical for the inactivation and metabolism of dopamine.

Ratios

vs
industry
vs
history
PB Ratio 5.67
CERC's PB Ratio is ranked lower than
73% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CERC: 5.67 )
Ranked among companies with meaningful PB Ratio only.
CERC' s PB Ratio Range Over the Past 10 Years
Min: 0.86  Med: 6 Max: 79.55
Current: 5.67
0.86
79.55
PS Ratio 6.81
CERC's PS Ratio is ranked higher than
83% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CERC: 6.81 )
Ranked among companies with meaningful PS Ratio only.
CERC' s PS Ratio Range Over the Past 10 Years
Min: 0.59  Med: 4.77 Max: 58.67
Current: 6.81
0.59
58.67
EV-to-EBIT -3.96
CERC's EV-to-EBIT is ranked higher than
58% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CERC: -3.96 )
Ranked among companies with meaningful EV-to-EBIT only.
CERC' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.7  Med: -0.3 Max: 17.1
Current: -3.96
-4.7
17.1
EV-to-EBITDA -4.41
CERC's EV-to-EBITDA is ranked higher than
64% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CERC: -4.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
CERC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.3  Med: -0.3 Max: 13.5
Current: -4.41
-5.3
13.5
EV-to-Revenue 9.10
CERC's EV-to-Revenue is ranked higher than
75% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CERC: 9.10 )
Ranked among companies with meaningful EV-to-Revenue only.
CERC' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.3  Med: 4.6 Max: 46.4
Current: 9.1
-0.3
46.4
Current Ratio 0.74
CERC's Current Ratio is ranked lower than
93% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CERC: 0.74 )
Ranked among companies with meaningful Current Ratio only.
CERC' s Current Ratio Range Over the Past 10 Years
Min: 0.51  Med: 1.31 Max: 5.82
Current: 0.74
0.51
5.82
Quick Ratio 0.70
CERC's Quick Ratio is ranked lower than
93% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CERC: 0.70 )
Ranked among companies with meaningful Quick Ratio only.
CERC' s Quick Ratio Range Over the Past 10 Years
Min: 0.51  Med: 1.31 Max: 5.82
Current: 0.7
0.51
5.82
Days Inventory 77.75
CERC's Days Inventory is ranked lower than
66% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. CERC: 77.75 )
Ranked among companies with meaningful Days Inventory only.
CERC' s Days Inventory Range Over the Past 10 Years
Min: 77.75  Med: 109.61 Max: 109.61
Current: 77.75
77.75
109.61
Days Sales Outstanding 70.51
CERC's Days Sales Outstanding is ranked higher than
77% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. CERC: 70.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
CERC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.79  Med: 42.24 Max: 70.51
Current: 70.51
41.79
70.51
Days Payable 92.91
CERC's Days Payable is ranked higher than
93% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. CERC: 92.91 )
Ranked among companies with meaningful Days Payable only.
CERC' s Days Payable Range Over the Past 10 Years
Min: 92.91  Med: 745.5 Max: 745.5
Current: 92.91
92.91
745.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -89.00
CERC's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CERC: -89.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CERC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -89  Med: -57.9 Max: -26.8
Current: -89
-89
-26.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.43
CERC's Price-to-Median-PS-Value is ranked higher than
64% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CERC: 1.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CERC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.98 Max: 7.98
Current: 1.43
0.14
7.98
Earnings Yield (Greenblatt) % -25.30
CERC's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CERC: -25.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CERC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8281.3  Med: -55.9 Max: 6740.4
Current: -25.3
-8281.3
6740.4

More Statistics

Revenue (TTM) (Mil) $15.58
EPS (TTM) $ -1.25
Beta1.36
Volatility93.70%
52-Week Range $2.00 - 5.74
Shares Outstanding (Mil)31.27

Analyst Estimate

Dec18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.87
EPS without NRI ($) -0.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}